Advertisement
Advertisement
February 8, 2011
Concentric Begins TREVO 2 Trial Enrollment
February 9, 2011—Concentric Medical, Inc. (Mountain View, CA) announced that the first patients were enrolled in the TREVO 2 (Thrombectomy Revascularization of Large Vessel Occlusions) pivotal clinical trial investigating the safety and efficacy of the company's Trevo Retriever for removing clot from ischemic stroke patients. The Trevo Retriever uses Concentric's Stentriever technology, which is designed for retrieving clot from the neurovasculature. Helmi Lutsep, MD, is the national coprincipal investigator of TREVO 2.
The Trevo Retriever was launched in Europe and other international markets in 2010.
"The experience with Stentriever devices in Europe is very encouraging,” commented Kenneth Liebman, MD. “We expect the Trevo Retriever to be more effective and to treat patients more quickly and ultimately expand endovascular treatment to more stroke patients in years to come."
Advertisement
Advertisement
